12 results about "Leonurus heterophyllus" patented technology

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating osteoporosis and a preparation and application thereof. The pharmaceutical composition is prepared from icariin, echinacoside, leonurus glycoside and cordycepin as raw materials according to a certain weight percentage. The traditional Chinese medicine composition can be prepared into various clinical common oral preparations. Pharmacological experiments show that the pharmaceutical composition can significantly inhibit the formation of osteoclasts in vitro. In addition, the pharmaceutical composition disclosed by the invention can be used for remarkably improving the bone mineral density value and the number of bone trabecula of ovariectomized mice. Experimental results also show that after icariin, echinacoside, leonurus glycoside and cordycepin are combined for use, a remarkable synergistic interaction effect is achieved. The pharmaceutical composition disclosed by the invention has a prospect of being developed into a medicine for treating osteoporosis, and has important social benefits and economic benefits.

The application discloses a traditional Chinese medicine composition for improving facial red blood vessels, an extract, and a preparation method and application thereof. The traditional Chinese medicine composition is composed of Leonurus japonicus and Corydalis remota. The traditional Chinese medicine composition is subjected to water extraction, and butanediol is selectively added to obtain the extract for improving facial red blood vessels. The traditional Chinese medicine composition or the extract can significantly improve facial red blood vessels, has no adverse reaction, is low in cost, and provides another way for improving facial red blood vessels for users with individual differences.

The invention provides a traditional Chinese medicine composition for treating cerebral small vascular diseases as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 300 parts of astragalus membranaceus, 50 parts of leech, 100 parts of safflower carthamus, 100 parts of ligusticum wallichii, 90 parts of acorus calamus, 100 parts of radix puerariae, 200 parts of caulis spatholobi, 100 parts of glossy privet fruit, 100 parts of leonurus japonicus, 200 parts of poria cocos and 100 parts of radix puerariae. The invention also relates to a preparation method and application of the composition. The traditional Chinese medicine composition disclosed by the invention has the effects of tonifying qi and activating blood, nourishing liver and kidney, relieving dizziness and restoring consciousness, and inducing diuresis and dredging collaterals, and can effectively improve the cognitive function, gait disorder and other symptoms of a patient with the cerebral small vascular disease; the traditional Chinese medicine composition is high in safety, small in side effect and suitable for being taken for a long time; the preparation method of the traditional Chinese medicine composition is simple, low in cost and easy for industrial production.

The invention provides syringic acid as well as preparation, a pharmaceutical composition and medical application thereof. The purity of the syringic acid is 95% or above, and the syringic acid can be extracted from motherwort. The syringic acid disclosed by the invention has a good dissolving effect on fibrin in thrombus formation, is relatively high in blood-brain barrier transmittance, has thrombus dissolving and antithrombotic effects, and can be used for preparing medicines for treating thrombotic diseases. The syringic acid can be processed into oral preparations such as tablets, capsules, granules, dripping pills and other common preparations or sustained release preparations, injection preparations such as injection freeze-dried powder injections, and external preparations such as ointments or emulsifiable paste according to a conventional production process of pharmaceutics, and is used for treating thrombotic diseases, especially cerebral thrombosis diseases.

The invention provides a traditional Chinese medicine composition for treating heart failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components: 1-12 parts of rohdea japonica, 1-12 parts of codonopsis pilosula, 1-12 parts of astragalus membranaceus, 1-12 parts of cassia twig, 1-8 parts of bighead atractylodes rhizome, 1-12 parts of poria cocos, 1-12 parts of radix ophiopogonis, 2-14 parts of semen lepidii, 1-10 parts of radix aconiti lateralis preparata, 1-10 parts of schisandra chinensis, 1-12 parts of hairyvein agrimony, 1-10 parts of pseudo-ginseng, 1-12 parts of epimedium, 1-12 parts of leonurus, 1-10 parts of ligusticum wallichii, 2-14 parts of salvia miltiorrhiza, 2-12 parts of radix sophorae flavescentis and 1-8 parts of liquorice. The traditional Chinese medicine composition can enhance myocardial contractility, increase coronary artery blood flow volume, protect myocardial cells, improve heart functions, obviously improve the heart functions and left ventricular remodeling, discharge liquid retained at the time of heart failure, relieve the pre-load of the heart and relieve edema; load during cardiac contraction is reduced, and excessive work of the heart is avoided.

This invention belongs to the field of traditional Chinese medicine research technology, specifically relating to a traditional Chinese medicine composition for treating coronary heart disease, its preparation method, and its application. The traditional Chinese medicine composition is made from the following raw materials in parts by weight: Astragalus membranaceus 15-30 parts, Trichosanthes kirilowii 15-30 parts, Inula japonica 9-12 parts, Rubia cordifolia 9-12 parts, Ligusticum chuanxiong 9-12 parts, Salvia miltiorrhiza 15-30 parts, Leonurus japonicus 9-15 parts, Aucklandia lappa 6-9 parts, and Amomum villosum 3-6 parts. This traditional Chinese medicine composition has a good therapeutic effect on inflammatory factors in patients with coronary heart disease exhibiting qi deficiency and phlegm stasis syndrome, and no other adverse reactions such as liver or kidney damage have been observed in the patients.

The present invention provides a kind of pharmaceutical composition for treating chronic glomerulonephritis, it is the preparation prepared from the following bulk drug by weight ratio: 32-48 parts of Astragalus, 12-18 parts of Codonopsis, 12-18 parts of Rehmannia, 16-24 parts of Cornus, 16-24 parts of Poria, 12-18 parts of Euryale, 12-18 parts of Pyrilaria, 24-36 parts of Leonurus, 12-18 parts of Eucommia, 16-24 parts of Achyranthes, 24-36 parts of Houttuynia, 16-24 parts of Imperata Rhizome, 12-18 parts of Galla, 12-18 parts of Chinese Yam, 4.8-7.2 parts of Oryza Sativa. The present invention also provides the preparation method and purposes of the pharmaceutical composition. The medicine of the present invention belongs to Chinese medicine preparation, and no obvious toxic and side effects are found through clinical studies, and after significantly reducing the urine protein level of the patient, the urine protein level can be well stabilized, which is beneficial to treatment, greatly enhances the patient's treatment enthusiasm, and provides a new medication selection for clinical use.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

The invention relates to the technical field of cardiomyopathy prevention and treatment, and discloses a traditional Chinese medicine for preventing and treating cardiomyopathy. The compound traditional Chinese medicine extract components comprise 10-15 parts of salvia miltiorrhiza, 10-15 parts of ligusticum wallichii, 3-5 parts of radix paeoniae rubra, 6-8 parts of radix achyranthis bidentatae, 3-5 parts of bamboo leaves, 10-15 parts of radix scutellariae, 8-12 parts of radix puerariae, 8-12 parts of astragalus membranaceus, 4-6 parts of rhodiola rosea, 8-12 parts of ginkgo leaves, 3-5 parts of schisandra chinensis, 8-12 parts of radix bupleuri, 5-8 parts of pericarpium citri reticulatae viride, 7-10 parts of turmeric, 10-15 parts of leonurus and 3-5 parts of betel The invention further discloses a treatment method of the traditional Chinese medicine for preventing and treating cardiomyopathy. The treatment method comprises the following steps: S1, crushing traditional Chinese medicine raw materials; s2, composite traditional Chinese medicine powder soaking; s3, decocting the soaked residues; s4, concentrating the filtrate; and S5, adding auxiliary materials. The traditional Chinese medicine composition can remarkably improve the symptoms of palpitation, weakness, dizziness, chest distress and breath shortness of a patient suffering from hypertrophic cardiomyopathy, and has a remarkable prevention and treatment effect on the hypertrophic cardiomyopathy.

The invention discloses a swertia-based bacteriostatic composition and a preparation method and application thereof, and belongs to the technical field of bacteriostatic agents. Swertia is used as a main bacteriostatic component, and cross-linking of peptidoglycan of bacterial cell walls is inhibited, so that synthesis of the cell walls is destroyed, the integrity of the bacterial cell walls is destroyed, and the antibacterial effect is improved. Therefore, the growth and reproduction of the staphylococcus aureus are inhibited. Secondly, the false Chinese swertia herb and the leonurine are compounded, so that on one hand, the destructive effect on cell walls of the staphylococcus aureus is enhanced, and on the other hand, in the glycolysis process of the staphylococcus aureus, the false Chinese swertia herb and the leonurine synergistically have a remarkable inhibition effect on hexokinase; therefore, the effect of inhibiting the growth and reproduction of the staphylococcus aureus is achieved by interfering the metabolic process of bacteria. And the destructive effect on a staphylococcus aureus biological membrane is improved through the assistance of nicotinic acid, so that the inhibition effect on staphylococcus aureus is enhanced.

This invention discloses the application of leonurin in the preparation of drugs for reducing serum total bilirubin levels, belonging to the field of traditional Chinese medicine technology. Through the construction of different types of hyperbilirubin animal models, this invention is the first to discover that leonurin can significantly reduce serum total bilirubin levels, and can be used to treat hyperbilirubinemia, alleviate bilirubin elevation caused by cholestasis, and treat acute abnormal bilirubin elevation. Simultaneously, leonurin does not cause abnormalities in liver function indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during the bilirubin-lowering process, demonstrating good safety. This invention also provides a pharmaceutical composition containing leonurin and its preparation method. This invention provides a new drug option for the treatment of hyperbilirubinemia.

The invention discloses a motherwort pretreatment device and method. The motherwort pretreatment device comprises a machine body, a transfer mechanism, a cutting mechanism, a cleaning mechanism and a driving mechanism, and the top of the machine body is of a step-shaped structure; the transfer mechanism is arranged at the stepped structure of the machine body in a stepped manner; the cut-off mechanism is connected to the step-shaped structure joint of the machine body in a penetrating mode. The cleaning mechanism is arranged in the machine body and comprises a water collecting part, a spraying part and a water pumping part; the driving mechanism is arranged in the machine body, and the output end of the driving mechanism is in transmission connection with the water pumping piece and the cut-off mechanism. The cutting-off mechanism achieves reciprocating cutting operation in an up-and-down reciprocating motion mode, a water pumping piece of the cleaning mechanism also pumps water from a water collecting piece in an up-and-down reciprocating mode, the pumped water is conveyed to a spraying piece to be sprayed, after the sprayed water cleans motherwort sections, sewage flows back and is collected in the water collecting piece, and therefore the motherwort sections are cleaned through the water pumping piece. Therefore, circulating water is formed, and water can be saved.